硫胺素作为糖尿病酮症酸中毒的辅助治疗
2026年5月26日 更新者:Michael Donnino、Beth Israel Deaconess Medical Center
这是一项随机、双盲、安慰剂对照试验,旨在确定静脉注射硫胺素是否会导致糖尿病酮症酸中毒入院患者的酸中毒更快消退。
研究人员将对硫胺素是否能改善细胞耗氧量、缩短重症监护病房 (ICU) 和住院时间或降低医院资源利用率进行二次调查。
研究概览
详细说明
硫胺素(维生素 B1)是一种水溶性维生素,在有氧葡萄糖代谢中起着关键作用。 硫胺素是丙酮酸脱氢酶 (PDH) 的辅助因子,丙酮酸脱氢酶是一种必须被激活才能进入有氧代谢的克雷布斯循环的酶。 PDH 活性在硫胺素缺乏状态下降低,导致丙酮酸代谢向厌氧途径转变。 这导致乳酸产生增加和酸中毒。 尿液中的硫胺素流失以及随之而来的硫胺素缺乏症在糖尿病中并不少见。 研究人员的初步研究发现,多达 39% 的 DKA 患者存在硫胺素缺乏症,并且硫胺素水平与乳酸和酸中毒呈负相关。 研究人员假设,用静脉注射硫胺素治疗 DKA 患者将导致更快地解决酸中毒和改善有氧代谢。 研究者的次要假设是,硫胺素治疗将缩短在 ICU 和医院的停留时间,并减少医院资源的利用。
在这项随机、双盲、安慰剂对照试验中,因 DKA 入院并参加研究的患者将被随机分配接受每天两次静脉注射硫胺素(200 毫克在 0.9% 生理盐水中),持续两天或等量的0.9% 盐水按相同的时间表。 研究者的主要结果是在登记后 24 小时内碳酸氢盐的变化,使用线性混合效应模型在 0、6、12、18、24 小时进行测量。 其次,患者将按 I 型和 II 型 DM 进行分层。 此外,将对缺乏硫胺素的受试者进行预先计划的子分析。
研究类型
介入性
注册 (实际的)
102
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Beth Israel Deaconess Medical Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
描述
纳入标准:
- 碳酸氢盐 ≤15 mEq/L
- 阴离子间隙 > 12 mEq/L
- 血液 pH≤ 7.24(如果临床团队已经获得)
- 尿酮(定性)或血清酮(β-羟基丁酸)> 3 mmol/L
- 演示后 6 小时内注册
排除标准:
- 当前每天补充硫胺素 ≥ 6 毫克(即超过多种维生素)
- 严重酸中毒的竞争性原因包括癫痫发作、一氧化碳中毒、氰化物中毒、心脏骤停、肝功能障碍(特别定义为已知肝硬化)
- 已知对硫胺素过敏
- 由临床团队判断的硫胺素给药的竞争适应症(例如,酒精)
- 研究保护人群(孕妇、囚犯、智障人士)
- 先前参加同一研究的患者
- 不复苏/不插管 (DNR/DNI) 或仅舒适措施 (CMO) 的代码状态
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:硫胺素
200mg 硫胺素在 50mL 0.9% 盐水中,每天两次,持续 2 天
|
硫胺素 200mg IV 每 12 小时一次,持续 2 天
其他名称:
|
|
安慰剂比较:安慰剂
100mL 0.9% 生理盐水,每天两次,连续两天
|
50mL 0.9% 生理盐水
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma Bicarbonate Levels
大体时间:6, 12, 18, and 24 hours after enrollment
|
Primary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lactate
大体时间:6, 12, 18, and 24 hours after enrollment
|
Secondary outcome of lactate over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
|
Anion Gap
大体时间:6, 12, 18, and 24 hours after enrollment
|
Secondary outcome of anion gap over 24 hours (6, 12, 18, 24 hours) following enrollment
|
6, 12, 18, and 24 hours after enrollment
|
|
ICU Length of Stay
大体时间:45 days
|
ICU length of stay reflects the number of ICU admission days.
|
45 days
|
|
Hospital Length of Stay
大体时间:45 days
|
Hospital length of stay reflects how long it takes a diabetic ketoacidosis patient to recover to the point where he/she can be released from the hospital.
|
45 days
|
|
Duration of Insulin Therapy
大体时间:First 7 days after enrollment
|
The duration of insulin therapy is calculated by examining the hospital clinical information systems for all records of IV insulin infusion beginning at the time of enrollment.
The start and the stop time-stamps of medication infusion are used to calculate a duration of infusion.
|
First 7 days after enrollment
|
|
SOFA Score (Sequential Organ Failure Assessement Score)
大体时间:24 hours
|
The SOFA score is a validated measure of organ dysfunction commonly used in critically ill patients, particularly those with sepsis.
It evaluates the function of six organ systems-respiratory, cardiovascular, neurologic, hepatic, renal, and coagulation-based on routinely collected clinical and laboratory data.
Each organ system is assigned a score from 0 (normal function) to 4 (most severe dysfunction), resulting in a total score ranging from 0 to 24.
Higher SOFA scores indicate greater severity of organ failure and a higher risk of adverse outcomes.
SOFA score in this study uses a modification in which the arterial oxygen saturation/fraction of inspired oxygen (SaO2 /FiO2) ratio is substituted for the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2 /FiO2 ratio).
|
24 hours
|
|
Oxygen Consumption by Circulating Mononuclear Cells
大体时间:24 hours
|
Oxygen consumption rate of circulating peripheral blood mononuclear cells measured using Seahorse.
Basal respiration represents oxygen consumption under baseline conditions.
ATP-linked respiration represents oxygen consumption coupled to ATP production, while proton leak represents oxygen consumption not linked to ATP synthesis.
Maximal respiration represents the maximal capacity of the electron transport chain after uncoupling.
Spare respiratory capacity represents the difference between maximal and basal respiration and indicates the ability to respond to increased energy demand.
Non-mitochondrial respiration represents oxygen consumption independent of mitochondrial activity.
|
24 hours
|
|
Pyruvate Dehydrogenase Activity
大体时间:24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
|
Secondary outcome of change in PDH specific activity over 72 hours or at discharge if patient's hospital length of stay was less than 72 hours.
PDH activity and total PDH protein quantity were measured in isolated peripheral blood mononuclear cells (PBMCs) following selective disruption of the mitochondrial membrane, using a previously validated immunocapture and microplate-based enzymatic assay protocol.
PDH-specific activity was calculated as the ratio of measured PDH enzymatic activity to the natural logarithm of PDH protein quantity (PDH activity / ln[PDH quantity]), providing a normalized metric that reflects the functional efficiency of the enzyme independent of its expression level.
Higher values suggest higher enzymatic efficiency.
|
24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
|
|
Neurocognitive: Hopkins Verbal Learning Test - Total Recall
大体时间:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall score is a measure of verbal learning and immediate memory.
Participants are read a list of 12 words (from three semantic categories) and asked to recall as many words as possible across three consecutive learning trials.
The Total Recall score is calculated as the sum of correctly recalled words across the three trials, yielding a possible range of 0 to 36, with higher scores indicating better verbal learning and memory performance.
This score reflects both initial acquisition and short-term retention of verbal information and is commonly used to assess cognitive function in clinical research.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Delayed Recall
大体时间:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall score assesses retention of verbal information after a delay.
Following completion of the three learning trials, participants are asked to recall the previously presented word list after a delay period (typically 20-25 minutes) without re-exposure to the words.
The Delayed Recall score is calculated as the number of correctly recalled words, with a possible range of 0 to 12, where higher scores indicate better memory retention.
This measure reflects the ability to consolidate and retrieve learned information over time and is commonly used to evaluate memory function in clinical and research settings.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Retention
大体时间:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Retention (%) score reflects the proportion of learned information that is retained over a delay.
It is calculated as the ratio of the Delayed Recall score to the highest number of words recalled on any of the three immediate recall trials, multiplied by 100, yielding a percentage value.
Scores typically range from 0% to 100%, with higher values indicating better retention of previously learned material.
This measure provides an index of memory retention independent of initial learning performance.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Hopkins Verbal Learning Test - Recognition Discrimination Index
大体时间:At hospital discharge, median of 4 days
|
The Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index assesses recognition memory by evaluating the ability to distinguish previously learned words from novel distractors.
During the recognition phase, participants are presented with a list of target words and distractor words and asked to identify those that were previously learned.
The Recognition Discrimination Index is calculated as the number of true positives (correctly identified target words) minus the number of false positives (incorrectly identified distractor words), yielding a score typically ranging from -12 to 12. Higher scores indicate better recognition accuracy and discrimination ability, reflecting the integrity of memory retrieval processes.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Brief Visuospatial Memory Test
大体时间:At hospital discharge, median of 4 days
|
The Brief Visuospatial Memory Test (BVMT) assesses visuospatial learning and memory.
Participants are shown six geometric designs for a brief period and asked to reproduce them from memory across three learning trials.
Performance is scored based on the accuracy and placement of each design, with a total recall score ranging from 0 to 36, where higher scores indicate better visuospatial memory.
A delayed recall trial is administered after a delay to assess retention of visual information.
This measure evaluates the ability to encode, store, and retrieve visuospatial material.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Trail Making Test - Test Part A
大体时间:At hospital discharge, median of 4 days
|
The Trail Making Test Part A (TMT-A) assesses visual attention, processing speed, and psychomotor function.
Participants are instructed to connect numbered circles in sequential order as quickly as possible.
The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance.
There is no fixed maximum score, although testing is typically discontinued at a predefined time limit (commonly 300 seconds).
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Trail Making Test - Test Part B
大体时间:At hospital discharge, median of 4 days
|
The Trail Making Test Part B (TMT-B) assesses executive function, including cognitive flexibility and set-shifting, in addition to processing speed.
Participants are required to alternate between numbers and letters in sequence (e.g., 1-A-2-B) as quickly as possible.
The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance.
As with TMT-A, there is no fixed maximum score, and testing is typically discontinued at a predefined time limit (commonly 300 seconds).
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: WAIS-IV Digit Span
大体时间:At hospital discharge, median of 4 days
|
The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span subtest assesses attention, working memory, and concentration.
Participants are asked to repeat sequences of numbers in forward order (Digit Span Forward), reverse order (Digit Span Backward), and ascending order (Digit Span Sequencing).
Scores are based on the total number of correctly recalled sequences, with higher scores indicating better attention and working memory capacity.
The total score ranges from 0 to 48.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Test of Verbal Fluency and Animal Naming
大体时间:At hospital discharge, median of 4 days
|
The Animal Naming test is a measure of semantic verbal fluency and executive function.
Participants are asked to name as many animals as possible within a fixed time period.
The score is the total number of unique, correct animal names generated, with higher scores indicating better semantic memory retrieval and executive functioning.
Scores range from 0 with no fixed upper limit.
|
At hospital discharge, median of 4 days
|
|
Neurocognitive: Test of Premorbid Functioning
大体时间:At hospital discharge, median of 4 days
|
The Test of Premorbid Functioning (TOPF) estimates an individual's baseline cognitive ability prior to illness or injury.
Participants are asked to read aloud a list of irregularly spelled words, and performance is scored based on correct pronunciation.
Scores are used to estimate premorbid intellectual functioning.
Scores range from 0 to 70, with higher scores indicating higher estimated premorbid functioning.
This measure helps contextualize current cognitive performance relative to expected baseline levels.
|
At hospital discharge, median of 4 days
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
C-peptide Levels
大体时间:0, 24 hours, and 72 hours (or at discharge if hospital length of stay was less than 72 hours)
|
C-peptide levels measured at time of study drug administration, 24 hours, and at 72 hours (or at discharge if hospital length of stay was less than 72 hours).
|
0, 24 hours, and 72 hours (or at discharge if hospital length of stay was less than 72 hours)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Michael Donnino, MD、Beth Israel Deaconess Medical Center
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2018年11月21日
初级完成 (实际的)
2024年9月30日
研究完成 (实际的)
2024年10月1日
研究注册日期
首次提交
2018年10月22日
首先提交符合 QC 标准的
2018年10月22日
首次发布 (实际的)
2018年10月24日
研究记录更新
最后更新发布 (实际的)
2026年6月23日
上次提交的符合 QC 标准的更新
2026年5月26日
最后验证
2026年4月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2018P000475
- 1R01DK112886-01A1 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.